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Objectives This study evaluated Multidimensional Geriatric Assessment (MGA) as predictor of mor-
tality and major adverse cardiovascular and cerebral events (MACCE) after transcatheter aortic valve
implantation (TAVI).
Background Currently used global risk scores do not reliably estimate mortality and MACCE in
these patients.
Methods This prospective cohort comprised 100 consecutive patients 70 years undergoing TAVI.
lobal risk scores (Society of Thoracic Surgeons [STS] score, EuroSCORE) and MGA-based scores
cognition, nutrition, mobility, activities of daily living [ADL], and frailty index) were evaluated as
redictors of all-cause mortality and MACCE 30 days and 1 year after TAVI in regression models.
esults In univariable analyses, all predictors were signiﬁcantly associated with mortality and
ACCE at 30 days and 1 year, except for the EuroSCORE at 30 days and instrumental ADL at 30
ays and 1 year. Associations of cognitive impairment (odds ratio [OR]: 2.98, 95% conﬁdence interval
CI]: 1.07 to 8.31), malnutrition (OR: 6.72, 95% CI: 2.04 to 22.17), mobility impairment (OR: 6.65, 95%
I: 2.15 to 20.52), limitations in basic ADL (OR: 3.63, 95% CI: 1.29 to 10.23), and frailty index (OR:
.68, 95% CI: 1.21 to 11.19) with 1-year mortality were similar compared with STS score (OR: 5.47,
5% CI: 1.48 to 20.22) and EuroSCORE (OR: 4.02, 95% CI: 0.86 to 18.70). Similar results were found
or 30-day mortality and MACCE. Bivariable analyses, including STS score or EuroSCORE suggested
ndependent associations of MGA-based scores (e.g., OR of frailty index: 3.29, 95% CI: 1.06 to 10.15,
or 1-year mortality in a model including EuroSCORE).
onclusions This study provides evidence that risk prediction can be improved by adding MGA-
ased information to global risk scores. Larger studies are needed for the development and valida-
ion of improved risk prediction models. (J Am Coll Cardiol Intv 2012;5:489–96) © 2012 by the
merican College of Cardiology Foundation
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490Until recently, 2 treatment options for patients with symp-
tomatic severe aortic stenosis were available: surgical aortic
valve replacement (SAVR) and medical treatment, the latter
option with less favorable outcomes as compared with
SAVR (1). However, SAVR is frequently not performed in
patients with high operative risk, mainly elderly patients
with comorbid conditions (2,3). Recently, transcatheter
aortic valve implantation (TAVI) has been introduced as an
See page 497
alternative, less invasive treatment option and has been
shown to reduce mortality compared with medical treat-
ment in patients deemed inoperable (4). Therefore, TAVI
offers a promising alternative to
conservative treatment for severe
aortic stenosis of elderly, inoper-
able patients.
Currently, the risk for cardio-
surgical procedures is usually es-
timated using Society of Tho-
racic Surgeons (STS) score
and/or logistic EuroSCORE
(5). Recently, these global risk
scores have been deemed subop-
timal for the risk assessment of
elderly patients with aortic stenosis
(6–9). There are 3 main reasons:
first, these scores were mainly
derived in adults undergoing
cardiovascular surgery; second,
organ-specific (e.g., cardiac-
related) risk predictors are prob-
ably under-represented in these
scores; third, specific geriatric
conditions that are not measured
by these scores may have a major
impact on prognosis in elderly
patients. Multidimensional Ge-
riatric Assessment (MGA) is a
iagnostic process intended to determine an older person’s
edical and functional resources and problems (10). MGA
onsists of several components, some of which assess cognitive
nd functional capacity. Components of MGA have proven
heir usefulness for risk prediction in elderly patients with acute
edical illness (11–14). Only a few studies have hitherto
valuated measures from MGA for the prediction of surgical
utcomes and found a significant predictive ability (15–20). So
ar, there is no study having assessed MGA-based scores to
stimate risk related to TAVI. The present study, therefore,
valuated MGA-based scores as predictors of mortality and
ajor adverse cardiovascular and cerebral events (MACCE) in
Abbreviations
and Acronyms
BADL  Basic Activities
of Daily Living
CI  confidence interval
IADL  Instrumental
Activities of Daily Living
MACCE  major adverse
cardiovascular and cerebral
events
MGA  Multidimensional
Geriatric Assessment
MMSE  Mini Mental
State Examination
MNA  Mini Nutritional
Assessment
OR  odds ratio
SAVR  surgical aortic
valve replacement
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantation
TUG  Timed Get Up
and Go testatients undergoing TAVI. cMethods
Study population. Consecutive patients 70 years with
evere symptomatic aortic stenosis and referred for an
n-hospital evaluation for TAVI to Bern University Hospi-
al, Switzerland, between September 1, 2009 and December
1, 2010, were eligible for this study. Aortic stenosis was
onsidered severe if the effective orifice area was 1 cm2
and/or 0.6 cm2/m2 body surface area. An interdisciplinary
eam of interventional cardiologists and cardiac surgeons
eviewed the individual cases and formed a consensus on
reatment selection (TAVI, SAVR, or medical treatment).
he consensus was based on several parameters, including
natomic characteristics of the aortic root, vascular access
ite specifications, perioperative risk as calculated with the
ogistic EuroSCORE and the STS score, underlying co-
orbidities (previous cardiac surgery, pulmonary insuffi-
iency, liver cirrhosis, severe connective tissue disease, his-
ory of mediastinal radiotherapy, porcelain aorta), and
eneral impression. Patients with a logistic EuroSCORE
5% were advised to undergo SAVR or medical treatment.
he treatment was either selected during the in-hospital
valuation phase or in the following 1 to 2 weeks after
valuation. The following patients were excluded: 1) pa-
ients with a treatment other than TAVI (i.e., SAVR or
edical treatment); 2) patients who lived abroad and were
ot able to participate in the follow-up; and 3) patients in
hom TAVI was performed as an emergency procedure
Fig. 1). All other patients were asked for study participa-
ion. If they gave informed consent, MGA was performed.
f the patients who received MGA during the study period,
he following were also excluded: 1) patients who still
aited for TAVI after December 31, 2010; 2) patients who
ied before TAVI; 3) patients who crossed over to SAVR or
edical treatment after initial allocation to TAVI; and
) patients in whom the time between MGA and TAVI was
3 months. The final study population consisted of all
atients in whom TAVI and MGA was performed during
he study period. The cohort study complies with the
eclaration of Helsinki, was approved by the local ethics
ommittee, and all patients provided informed written
onsent.
Baseline examinations. All participating patients received
n extensive cardiologic and geriatric baseline examination
uring the in-hospital evaluation. Patient history was re-
orded, including symptoms, cardiovascular risk factors,
edication, prior cardiovascular events, and further comor-
idities. Physical examination included the measurement of
eight, height, and blood pressure. Left ventricular ejection
raction, aortic valve orifice area, and transvalvular mean
radient were measured with transthoracic or transesopha-
eal echocardiography. All patients underwent cardiac cath-
terization providing information about the presence of
oronary artery disease and hemodynamic evaluation of
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491transvalvular gradient, cardiac output, aortic valve area, and
right-sided filling pressures. Based on the gathered infor-
mation, STS score and logistic EuroSCORE were calcu-
lated. For the purpose of this analysis, both scores were
dichotomized at standard cut-points: STS score at 5%
(higher risk) versus 5% (lower risk) and logistic Euro-
CORE at 15% (higher risk) versus 15% (lower risk).
The baseline examination during the in-hospital evalua-
ion included an MGA consisting of validated instruments.
or this study, instruments assessing physiological function-
ng were selected; instruments for psychosocial functioning
ere not considered. The following instruments were used
n this study: Mini Mental State Exam (MMSE) (21); Mini
utritional Assessment (MNA) (22); Timed Get Up and
o test (TUG) (23); Basic Activities of Daily Living
Figure 1. Flow Chart: Patient Flow During Study
The ﬂow chart displays the patient ﬂow during the study. The study populatio
implantation (TAVI). MGA  multidimensional geriatric assessment.BADL), and Instrumental Activities of Daily Living (IADL) t(24); and questions about pre-clinical mobility disability
(25). For the purpose of this analysis, the instruments were
dichotomized at standard cut-points: MMSE at27 points
cognitive impairment improbable) versus 27 points (cog-
itive impairment probable), MNA at 12 points (malnu-
rition improbable) versus 12 points (malnutrition prob-
ble), and TUG at 20 s (moderate or severe limitation of
obility) versus 20 s (no or only slight limitation of
obility). BADL and IADL were considered abnormal if
here was at least 1 activity with a limitation. Pre-clinical
obility disability was considered present if in response to
he questions about mobility, the patient reported that the
requency of walking 200 m and/or of climbing stairs had
ecreased during the preceding 6 months.
Based on theoretical considerations from existing litera-
lly consisted of 100 patients who underwent transcatheter aortic valven ﬁnaure, a frailty index was constructed by the geriatrician
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492authors (A.W.S. and A.E.S.) before statistical analysis
(17,25). The intention of constructing a frailty index was to
have a quantitative measure of the patient’s general condi-
tion. The frailty index was defined as a summary score
calculated from instruments of the MGA: 2 points were
assigned if MMSE was21 points; 1 point was assigned for
each of the following: MMSE 21 and 27 points, MNA
12 points, TUG 20 s, BADL with at least 1 limited
ctivity, IADL with at least 1 limited activity, and a
re-clinical mobility disability. Thus, the frailty index had a
ange from 0 to 7 points. For the purpose of this analysis,
he frailty index was dichotomized at 3 points (frailty
robable) versus 3 points (frailty improbable).
TAVI procedure and follow-up. TAVI was performed after
he cardiologic and geriatric baseline examination, usually
ithin 2 weeks. The transcatheter aortic valve bioprosthesis
as introduced transfemorally whenever feasible. The
ransapical approach was reserved for patients with severe
eripheral vascular disease that precluded a transfemoral
pproach. The procedure was performed under local
nesthesia and mild conscious sedation using the
edtronic CoreValve (Medtronic, Minneapolis, Minne-
ota) in 63 patients and the Edwards Sapien XT biopros-
hesis (Edwards Lifesciences, Irvine, California) in 37
atients (26).
Patients were scheduled for a clinical follow-up 30 days
nd 1 year after TAVI. Endpoint adjudication was per-
ormed by a team of interventional cardiologists and car-
iovascular surgeons. All-cause mortality as well as
ACCE constituted the endpoints of this study (27,28).
Statistical methods. Baseline characteristics were described
y counts, percentages, and mean  SD. Univariable
ssociations between the clinical endpoints and the dichot-
mized risk scores were assessed by sample odds ratios and
-sided p values from a Fisher exact test or a chi-square test.
dditionally, the same risk measures were evaluated as
ontinuous linear variables in a logistic regression. For
nterpretational purposes, the measures were divided in
ubintervals. The MMSE was divided in subintervals of 3
oints to obtain odds ratios for a change of 3 points, and it
as analyzed reciprocally, as in contrast to all other scores in
he logistic regression, a lower MMSE score indicates a
ore severe limitation. The TUG was divided in subinter-
als of 5 s, and values 30 s were set to 30 s. We used a
ogistic regression for assessing bivariable associations of the
linical endpoints at 1 year with the STS score or logistic
uroSCORE and selected MGA-based risk scores as inde-
endent variables. Bivariable analyses only included MGA-
ased risk scores that showed statistically significant (p 
.05) associations in univariable analyses. Analyses were
erformed in Stata version 12.0 (Stata, College Station,
exas).esults
Between September 1, 2009, and December 31, 2010, 213
patients at least 70 years of age with severe aortic stenosis
were referred for evaluation for TAVI (Fig. 1). Of these, 93
fulfilled an exclusion criterion: 82 patients were excluded
owing to treatment selection other than TAVI, 6 patients
lived abroad and were not able to participate in the
follow-up, and in 5 patients, TAVI was performed as an
emergency procedure. An additional 10 patients were ex-
cluded because they were still waiting for TAVI after
December 31, 2010, because they died before TAVI,
because they crossed over to medical treatment, or because
the time between baseline MGA and TAVI was 3
onths. Only 10 patients were not included and did not
eceive MGA although they fulfilled the inclusion criteria (7
atients due to logistic problems, and 3 patients who refused
GA). The study population finally consisted of 100
atients who underwent TAVI. In 85 patients (85.0%),
AVI was introduced transfemorally, in 14 patients (14.0%)
ransapically, and in 1 patient (1.0%) via subclavian artery.
The baseline characteristics of the study population are
hown in Table 1. Mean age was 83.7  4.6 years (range:
Table 1. Baseline Characteristics (N  100)
Age, yrs 83.7 4.6
Female 60 (60.0%)
Body mass index, kg/m2 25.6 4.6
Cardiovascular risk factors
Hypertension 87 (87.0%)
Hypercholesterolemia 67 (67.0%)
Current smoker 3 (3%)
Diabetes 26 (26.0%)
Family history of CAD 18 (18.0%)
Medical history
CAD 66 (66.0%)
Previous myocardial infarction 13 (13.0%)
Previous stroke 4 (4.0%)
Chronic heart failure 30 (30.0%)
Symptoms
Dyspnea NYHA functional class III or IV 50 (50.0%)
Angina CCS III or IV 19 (19.0%)
Previous syncope 11 (11.0%)
Medication
ACEI/ARB 49 (49.0%)
Diuretic 65 (65.0%)
Beta-blocker 51 (51.0%)
Echocardiography
LVEF, % 50.5 14.1
Mean gradient aortic valve, mm Hg 43.0 15.9
Aortic valve area, cm2 0.6 0.2
Values are mean SD and n (%).
ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; CAD
coronary artery disease; CCS Canadian Cardiovascular Society; LVEF left ventricular ejectionfraction; NYHA New York Heart Association.
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49372.5 to 93.2 years), and 60% of the patients were women. As
a consequence of the age and sex distribution, the prevalence
of hypertension and diabetes was rather high, whereas there
were only a few current smokers (Table 1). The mean STS
score was 6.3  3.3% (range: 1.9% to 16.9%), and the mean
logistic EuroSCORE 25.8 14.9% (range: 8.0% to 75.9%).
Table 2 summarizes the results of the baseline MGA.
MGA detected geriatric problems in a relevant proportion
of the patients. In the MMSE, almost every third patient
had findings compatible with cognitive impairment. The
MNA found probable malnutrition in more than 2 of 5
patients. The TUG revealed a moderate or severe limitation
of mobility in almost 2 of 5 patients. According to the frailty
index, 49.0% of the patients were considered frail.
Of the 100 study participants, 19 died within 1-year
follow-up, of whom 8 died during the first 30 days of
follow-up. A MACCE (including the patients who experi-
enced cardiac death) was observed in 22 patients within
1-year follow-up; the MACCE occurred during the first 30
days in 10 of these patients. STS score, logistic Euro-
SCORE, and MGA-based risk scores were evaluated in
univariable regression models for their ability to predict
all-cause mortality and the occurrence of MACCE 30 days
and 1 year after TAVI (Table 3). The STS score showed a
strong association with all-cause mortality and MACCE 30
days and 1 year after TAVI. The logistic EuroSCORE was
not significantly associated with all-cause mortality or
MACCE 30 days after TAVI. At 1 year, the logistic
EuroSCORE showed evidence for an association with
all-cause mortality or MACCE, but only if used as a linear
measure. Of the MGA-based risk scores, MMSE, MNA,
TUG, BADL, and pre-clinical mobility disability, as well as
the frailty index, showed evidence of an association with
all-cause mortality and MACCE 30 days and 1 year after
TAVI (Table 3). IADL was not significantly associated
with the outcomes at 30 days and 1 year.
Table 2. Baseline Results of Global and MGA-Based
Risk Score Result
Global risk scores
STS score 5% At risk of
Logistic EuroSCORE 15% At risk of
MGA-based risk scores
MMSE 27 points Cognitive
MNA 12 points Malnutrit
TUG 20 s Moderate
BADL 1 point At least 1
IADL 1 point At least 1
Pre-clinical mobility disability Present Pre-clinic
Frailty index 3 points Frailty
BADL Basic Activities of Daily Living; IADL Instrumental ActivitiesMental State Examination; MNAMini Nutritional Assessment; STS SocietyBivariable regression models were performed to examine
the independent association of MGA-based risk scores with
mortality and MACCE 1 year after TAVI, if combined
with global risk scores in the same model (Table 4).
Bivariable analyses only included MGA-based risk scores
that showed statistically significant associations in univari-
able analyses. A strong evidence for an association of
MMSE, MNA, TUG, BADL, and the frailty index with
all-cause mortality and MACCE was found independent of
global risk scores.
Discussion
This analysis of a prospective cohort study of elderly
high-risk patients undergoing TAVI shows that MGA-
based risk scores perform similar to global risk scores for the
prediction of all-cause mortality and MACCE 30 days and
1 year after TAVI. Furthermore, associations of MGA-
based risk scores with mortality and MACCE were inde-
pendent of global risk scores. Of note, the significant
associations of the MGA-based scores with all-cause mor-
tality and MACCE were found in a small sample of 100
patients. This study, therefore, demonstrates that it is
possible to develop better risk scores for elderly patients
undergoing TAVI.
The development of new risk scores suitable for the
assessment of old patients has been claimed for many years
(9). So far, only a few studies have examined the predictive
capacity of geriatric instruments to predict important out-
comes such as mortality or relevant morbidity after surgery
(15–20). One recent study showed that a frailty measure
independently predicted post-operative complications,
length of stay, and discharge to an assisted-living facility in
older surgical patients (15). Two further studies found that
components of the MGA may predict adverse outcomes
following thoracic surgery (16,17). In accordance with these
cores
Interpretation
Proportion of Patients,
n (%) (n  100)
r mortality 56 (56.0%)
r mortality 72 (72.0%)
irment probable 32 (32.0%)
obable 44 (44.0%)
vere limitation of mobility 38 (38.0%)
activity with limitation 29 (29.0%)
mental activity with limitation 58 (58.0%)
ility disability 60 (60.0%)
49 (49.0%)
Living; MGAMultidimensional Geriatric Assessment; MMSEMiniRisk S
highe
highe
impa
ion pr
or se
basic
instru
al mob
of Dailyof Thoracic Surgeons; TUG Timed Get Up and Go test.
ratio; T
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494studies, our study confirms the high predictive potential of
MGA-based scores in patients who undergo TAVI.
The question arises why MGA-based scores have a high
predictive potential in old patients. MGA consists of several
well-validated screening instruments that are very sensitive
to detect a functional deterioration (21–24). MGA,
therefore, identifies those patients with diminished phys-
iological reserves and reduced adaptive capacity in mul-
tiple organ systems. Therefore, the MGA has the poten-
tial to differentiate between those old patients recovering
better than expected and those at risk of deteriorating
after an intervention.
Study limitations. First, it has to be recognized that patients
undergoing TAVI were a selection of elderly, high-risk
patients with an increased logistic EuroSCORE. Old pa-
tients with a low logistic EuroSCORE were in general
Table 3. Univariable Associations of Global and MGA-Based Risk Scores fo
1 Year After TAVI
30 Days After TA
All-Cause Mortality
OR (95% CI) p Value OR
Global risk scores
STS score
Linear (OR per 5% increase) 3.16 (1.24–8.06) 0.02 2.34
Dichotomized (5% vs. 5%) 6.14 (0.73–51.95) 0.08 8.23
Logistic EuroSCORE
Linear (OR per 10% increase) 1.32 (0.87–2.02) 0.20 1.27
Dichotomized (15% vs. 15%) 2.91 (0.34–24.78) 0.44 1.63
MGA-based risk scores
MMSE
Linear (OR per 3 points decrease) 2.85 (1.32–6.17) 0.01 3.67
Dichotomized (27 vs. 27 points) 7.62 (1.44–40.19) 0.01 6.07
MNA
Linear (OR per 1 point decrease) 1.30 (1.03–1.66) 0.03 1.31
Dichotomized (12 vs. 12 points) 10.41 (1.23–88.12) 0.02 3.34
TUG
Linear (OR per 5 s increase) 1.83 (1.10–3.05) 0.02 1.67
Dichotomized (20 vs. 20 s) 13.77 (1.62–117.01) 0.004 8.00
BADL
Linear (OR per 1 point increase) 1.75 (1.01–3.02) 0.05 2.13
Dichotomized (1 point) 4.72 (1.05–21.27) 0.04 4.37
IADL
Linear (OR per 1 point increase) 1.39 (0.91–2.11) 0.13 1.06
Dichotomized (1 point) 1.19 (0.27–5.31) 0.999 0.53
Pre-clinical mobility disability
dichotomized (present or not) 5.15 (0.61–43.59) 0.14 2.92
Frailty index
Linear (OR per 1 point increase) 2.18 (1.32–3.61) 0.002 1.66
Dichotomized (3 vs. 3 points) 8.33 (0.99–70.48) 0.03 4.78
CI confidence interval; MACCEmajor adverse cardiovascular and cerebral event(s); OR oddsallocated to SAVR, whereas elderly patients with excessiverisk were sometimes assigned to medical treatment. There-
fore, the predictive value of MGA has to be reconfirmed in
these patients with higher or lower risk, if in the future,
TAVI will also be performed in these populations. Second,
the findings of this study are based on data from a single
center. Therefore, confirmation in an independent sample is
of importance to improve generalizability of our findings.
Third, the sample size was small with 100 patients. This
number and the resulting number of endpoints were not
sufficient to evaluate MGA-based risk scores in multi-
variable models involving more than 2 predictor variables.
Hence, it was not possible to examine independent
associations of MGA-based scores together with further
scores that have been found to be predictive of outcomes
after TAVI, such as cardiac-related risk predictors (e.g.,
aortic mean gradient or tricuspid/mitral valve regurgita-
Prediction of All-Cause Mortality and MACCE 30 Days and
1 Year After TAVI
MACCE All-Cause Mortality MACCE
CI) p Value OR (95% CI) p Value OR (95% CI) p Value
5.50) 0.05 3.63 (1.71–7.71) 0.001 2.66 (1.33–5.34) 0.01
67.71) 0.04 5.47 (1.48–20.22) 0.01 3.40 (1.14–10.13) 0.03
1.88) 0.23 1.79 (1.27–2.53) 0.001 1.57 (1.15–2.16) 0.01
8.17) 0.72 4.02 (0.86–18.70) 0.09 2.99 (0.81–11.04) 0.11
8.32) 0.002 2.72 (1.40–5.31) 0.003 3.04 (1.53–6.03) 0.001
25.33) 0.01 2.98 (1.07–8.31) 0.03 3.48 (1.30–9.28) 0.01
1.63) 0.02 1.27 (1.06–1.52) 0.01 1.30 (1.09–1.55) 0.004
13.77) 0.10 6.72 (2.04–22.17) 0.001 6.42 (2.14–19.31) 0.001
2.60) 0.02 1.74 (1.24–2.45) 0.001 1.63 (1.19–2.24) 0.002
40.03) 0.01 6.65 (2.15–20.52) 0.001 5.12 (1.85–14.22) 0.001
3.56) 0.004 1.81 (1.16–2.84) 0.01 1.78 (1.15–2.77) 0.01
16.87) 0.03 3.63 (1.29–10.23) 0.01 3.33 (1.24–8.95) 0.01
1.62) 0.78 1.25 (0.92–1.70) 0.16 1.19 (0.88–1.59) 0.26
2.12) 0.48 1.52 (0.52–4.45) 0.44 1.55 (0.56–4.25) 0.40
14.55) 0.31 3.00 (0.92–9.83) 0.07 3.86 (1.20–12.44) 0.03
2.44) 0.01 1.80 (1.31–2.47) 0.001 1.80 (1.33–2.45) 0.001
23.77) 0.05 3.68 (1.21–11.19) 0.02 4.89 (1.64–14.60) 0.003
AVI transcatheter aortic valve implantation; other abbreviations as in Table 2.r the
VI
(95%
(0.99–
(1.00–
(0.86–
(0.32–
(1.62–
(1.45–
(1.05–
(0.81–
(1.08–
(1.60–
(1.27–
(1.13–
(0.70–
(0.13–
(0.59–
(1.14–
(0.96–tion) (29). However, the number of 19 mortality and 22
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2 Stortecky et al.
MA Y 2 0 1 2 : 4 8 9 – 9 6 Geriatric Assessment as Predictor After TAVI
495MACCE endpoints was sufficient to avoid overfitting in
the performed bivariable models (30).
The present study has research implications. First,
studies based on larger sample sizes are needed for the
derivation and validation of risk scores combining ele-
ments of MGA-based scores and other scores that have
been found to be predictive of outcomes after TAVI. In
particular, this applies to the combination with cardiac-
related risk predictors, such as aortic mean gradient or
tricuspid/mitral valve regurgitation (29). It is likely that
such risk scores may reach adequate predictive validity to
justify their use in clinical practice. Second, larger studies
are also needed to optimize MGA-based scores for the
risk prediction after TAVI. The MGA-based scores and
their cut-points used in this study were originally devel-
oped for diagnostic purposes, and the frailty index was
developed based on a priori considerations. It is likely
that MGA-based risk scores perform even better, if
adapted for TAVI risk prediction.
This study in addition has clinical implications. MGA is
still infrequently used in well-defined clinical situations,
such as for operative risk assessment. In view of a growing
population of old patients in industrialized nations, the
implementation of MGA in such conditions and others is
Table 4. Selection of Bivariable Associations of Global and MGA-Based Ris
Model
Components of
Model*
Models with STS score
Model 1 STS score 5
MMSE 2
Model 2 STS score 4
MNA 5
Model 3 STS score 4
TUG 5
Model 4 STS score 4
BADL 2
Model 5 STS score 4
Frailty index 2
Models with logistic EuroSCORE
Model 6 Logistic EuroSCORE 4
MMSE 3
Model 7 Logistic EuroSCORE 3
MNA 6
Model 8 Logistic EuroSCORE 3
TUG 6
Model 9 Logistic EuroSCORE 3
BADL 3
Model 10 Logistic EuroSCORE 3
Frailty index 3
*The risk scores were used as dichotomized variables using the cut-points outlined in theMethods
Abbreviations as in Tables 2 and 3.timely and indicated (31–33). In addition to the potentialbenefit of MGA to improve risk prediction, it also offers
detecting modifiable risk factors amenable to targeted peri-
operative interventions (e.g., malnutrition). Therefore,
MGA could also help improving the prognosis of patients
undergoing TAVI. A recent study demonstrated that hos-
pitalized patients, including surgical patients, benefit from
programs combining geriatric assessment with geriatric
management (34).
Conclusions
This study shows that MGA-based risk scores predict
all-cause mortality and MACCE in elderly patients under-
going TAVI. This study also shows that risk prediction of
other global risk scores may be improved using MGA-based
scores. Larger studies are needed to optimize MGA-based
scores for use in clinical routine.
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